|
|
| | Dalbavancin hydrochloride Basic information |
| | Dalbavancin hydrochloride Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO: ≥ 24 mg/mL (12.95 mM) | | form | Solid | | color | White to light yellow | | Water Solubility | Water: 50 mg/mL (26.98 mM) |
| | Dalbavancin hydrochloride Usage And Synthesis |
| Biological Activity | Dalbavancin hydrochloride(MDL-63397 hydrochloride) is a semi-synthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90 of 0.06 μg/mL and 0.25 μg/mL, respectively. | | in vitro | Dalbavancin is a parenterally administered semisynthetic lipoglycopeptide developed to combat infections caused by resistant gram-positive pathogens. Dalbavancin exhibits potent in vitro bactericidal activity against gram-positive pathogens including S. aureus (MRSA ), VISA, and non-VanA strains of VRE. Dalbavancin is developed for the treatment of complicated skin and skin structure infections (cSSSIs), predominantly those caused by MRSA and β-hemolytic streptococci , organisms against which it has shown greater potency than existing glycopeptide therapeutic agents. | | in vivo | Dalbavancin (15-240 mg/kg; intraperitoneal injection; every 36 h or 72 h; for 14 days; female BALB/c mice) treatment has a survival rate of 80% to 100% of mice with all dose regimens. | Animal Model: | Female BALB/c mice (6-8 weeks) challenged with Ames strain of B . anthracis | | Dosage: | 15 mg/kg, 30 mg/kg, 60 mg/kg, 120 mg/kg, 240 mg/kg | | Administration: | Intraperitoneal injection ; every 36 h or 72 h; for 14 days | | Result: | The efficacy was 80 to 100%, as determined by the rate of survival at 42 days, when treatment was initiated 24 h postchallenge with regimens of 15 to 120 mg/kg every 36 h or 30 to 240 mg/kg every 72 h. | |
| | Dalbavancin hydrochloride Preparation Products And Raw materials |
|